Fusing safety and efficacy: A maternal bivalent RSV prefusion F vaccine.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 37343524.
- Also identified by DOI 10.1016/j.xcrm.2023.101081 and PMC identifier 10313928.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In this phase 3 trial, Kampmann et al.<sup>1</sup> demonstrated safety and efficacy of a maternal bivalent RSV prefusion F vaccine. Vaccine efficacy was achieved in reducing severe RSV-associated lower respiratory tract infections in infants at 90 and 180 days following birth.
Medical subject headings
- Respiratory Syncytial Virus, Human
- Respiratory Syncytial Virus Vaccines
- Respiratory Syncytial Virus Infections